stocks logo

IMMX Valuation

Immix Biopharma Inc
$
2.750
+0.05(1.852%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

IMMX Relative Valuation

IMMX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMMX is overvalued; if below, it's undervalued.

Historical Valuation

Immix Biopharma Inc (IMMX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.69. The fair price of Immix Biopharma Inc (IMMX) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:2.70
Fair
-4.46
PE
1Y
3Y
5Y
Trailing
Forward
-2.71
EV/EBITDA
Immix Biopharma Inc. (IMMX) has a current EV/EBITDA of -2.71. The 5-year average EV/EBITDA is -2.23. The thresholds are as follows: Strongly Undervalued below -6.71, Undervalued between -6.71 and -4.47, Fairly Valued between 0.01 and -4.47, Overvalued between 0.01 and 2.24, and Strongly Overvalued above 2.24. The current Forward EV/EBITDA of -2.71 falls within the Historic Trend Line -Fairly Valued range.
-2.82
EV/EBIT
Immix Biopharma Inc. (IMMX) has a current EV/EBIT of -2.82. The 5-year average EV/EBIT is -2.09. The thresholds are as follows: Strongly Undervalued below -6.27, Undervalued between -6.27 and -4.18, Fairly Valued between 0.00 and -4.18, Overvalued between 0.00 and 2.09, and Strongly Overvalued above 2.09. The current Forward EV/EBIT of -2.82 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Immix Biopharma Inc. (IMMX) has a current PS of 0.00. The 5-year average PS is 6.06. The thresholds are as follows: Strongly Undervalued below -38.90, Undervalued between -38.90 and -16.42, Fairly Valued between 28.54 and -16.42, Overvalued between 28.54 and 51.02, and Strongly Overvalued above 51.02. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Immix Biopharma Inc. (IMMX) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.20. The thresholds are as follows: Strongly Undervalued below -4.61, Undervalued between -4.61 and -2.91, Fairly Valued between 0.50 and -2.91, Overvalued between 0.50 and 2.20, and Strongly Overvalued above 2.20. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Immix Biopharma Inc. (IMMX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Immix Biopharma Inc (IMMX) has a current Price-to-Book (P/B) ratio of 7.90. Compared to its 3-year average P/B ratio of 3.05 , the current P/B ratio is approximately 158.62% higher. Relative to its 5-year average P/B ratio of 2.84, the current P/B ratio is about 178.27% higher. Immix Biopharma Inc (IMMX) has a Forward Free Cash Flow (FCF) yield of approximately -17.75%. Compared to its 3-year average FCF yield of -24.38%, the current FCF yield is approximately -27.20% lower. Relative to its 5-year average FCF yield of -21.41% , the current FCF yield is about -17.10% lower.
7.90
P/B
Median3y
3.05
Median5y
2.84
-17.75
FCF Yield
Median3y
-24.38
Median5y
-21.41

Competitors Valuation Multiple

The average P/S ratio for IMMX's competitors is 500.49, providing a benchmark for relative valuation. Immix Biopharma Inc Corp (IMMX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

Performance Decomposition

1Y
3Y
5Y
Market capitalization of IMMX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IMMX in the past 1 year is driven by Unknown.

FAQ

arrow icon

Is Immix Biopharma Inc (IMMX) currently overvalued or undervalued?

Immix Biopharma Inc (IMMX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.69. The fair price of Immix Biopharma Inc (IMMX) is between to according to relative valuation methord.
arrow icon

What is Immix Biopharma Inc (IMMX) fair value?

arrow icon

How does IMMX's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Immix Biopharma Inc (IMMX) as of Jul 30 2025?

arrow icon

What is the current FCF Yield for Immix Biopharma Inc (IMMX) as of Jul 30 2025?

arrow icon

What is the current Forward P/E ratio for Immix Biopharma Inc (IMMX) as of Jul 30 2025?

arrow icon

What is the current Forward P/S ratio for Immix Biopharma Inc (IMMX) as of Jul 30 2025?